John F Tisdale
National Heart, Lung, and Blood Institute (NHLBI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
17
all conditions, ClinicalTrials.gov
NIH grants tied to them
8
5 more share only the name and are not shown
Trial papers
17
PubMed author-name match
Trials
Studies that name John F Tisdale as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:59 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07599176 · Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsNational Heart, Lung, and Blood Institute (NHLBI) · recruiting · Sickle Cell Disease, Beta-thalassemia · principal investigator
- Early Ph1NCT06313398 · Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin LabelingNational Heart, Lung, and Blood Institute (NHLBI) · recruiting · Sickle Cell Disease, Thalassemia, Hemoglobinopathy · principal investigator
- Ph1/Ph2NCT05357482 · Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-ThalassemiaNational Heart, Lung, and Blood Institute (NHLBI) · active not recruiting · Sickle Cell Anemia, Beta Thalassemia · principal investigator
- Early Ph1NCT04476277 · Red Cell Half Life Determination in Patients With and Without Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI) · completed · Sickle Cell Disease, Sickle Cell Anemia · principal investigator
- N/ANCT04349189 · Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell TraitNational Heart, Lung, and Blood Institute (NHLBI) · completed · Sickle Cell Disease, Venous Thrombosis, Sickle Cell Trait · principal investigator
- Ph1NCT03226691 · Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) PatientsNational Heart, Lung, and Blood Institute (NHLBI) · completed · Sickle Cell Disease · principal investigator
- N/ANCT01547793 · Carbon Monoxide Levels and Sickle Cell Disease SeverityNational Heart, Lung, and Blood Institute (NHLBI) · completed · Sickle Cell Disease, Sickle Cell Anemia, Anemia, Sickle Cell · principal investigator
- Ph2NCT00508989 · Niacin to Improve Blood Flow in People With Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI) · completed · Sickle Cell Disease · principal investigator
- Ph1NCT00352430 · Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary HypertensionNational Heart, Lung, and Blood Institute (NHLBI) · completed · Pulmonary Hypertension · principal investigator
- Ph1NCT00270478 · Hydroxyurea and Erythropoietin to Treat Sickle Cell AnemiaNational Heart, Lung, and Blood Institute (NHLBI) · completed · Sickle Cell Disease, Chronic Kidney Disease, Pulmonary Hypertension · principal investigator
- Ph1NCT00095472 · Therapeutic Application of Intravascular Nitrite for Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI) · completed · Sickle Cell Anemia · principal investigator
- Ph1NCT00072826 · Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell DiseaseNational Institutes of Health Clinical Center (CC) · completed · Sickle Cell Disease · principal investigator
- Ph1/Ph2NCT00061568 · Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital AnemiasNational Heart, Lung, and Blood Institute (NHLBI) · active not recruiting · Congenital Hemolytic Anemia, Sickle Cell Disease · principal investigator
- Ph1NCT00056433 · Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell AnemiaNational Institutes of Health Clinical Center (CC) · completed · Sickle Cell Anemia · principal investigator
- N/ANCT00033774 · Stem Cell Collection for Adult VolunteersNational Heart, Lung, and Blood Institute (NHLBI) · terminated · Sickle Cell · principal investigator
- Ph1NCT00023296 · Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary HypertensionNational Heart, Lung, and Blood Institute (NHLBI) · completed · Sickle Cell Anemia, Pulmonary Hypertension · principal investigator
- N/ANCT00012545 · Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell DiseaseNational Heart, Lung, and Blood Institute (NHLBI) · completed · Sickle Cell Disease, Sickle Cell Trait · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Isolation, characterization, and transplantation of candidate stem cellsZIAHL006009 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2009 to 2025 · $1,457,612 awarded in 2025Same name and institution; not confirmed by an ID
- Nonmyeloablative allogeneic PBSC in globin disordersZIAHL006007 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2009 to 2025 · $1,943,482 awarded in 2025Same name and institution; not confirmed by an ID
- Preclinical and Clinical Studies in Gene Therapy for Sickle Cell DiseaseZIAHL006008 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2009 to 2025 · $1,457,612 awarded in 2025Same name and institution; not confirmed by an ID
- Development of improved lentiviral vectors for human gene therapy applicationsZIAHL006010 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2009 · $205,756 awarded in 2009Same name and institution; not confirmed by an ID
- A preclinical large animal model for globin gene transferZ01HL006008 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2008 · $329,550 awarded in 2008Same name and institution; not confirmed by an ID
- Development of improved lentiviral vectors for human gene therapy applicationsZ01HL006010 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2008 · $164,775 awarded in 2008Same name and institution; not confirmed by an ID
- Isolation, characterization, and transplantation of candidate stem cellsZ01HL006009 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2008 · $219,700 awarded in 2008Same name and institution; not confirmed by an ID
- Nonmyeloablative allogeneic PBSC in globin disordersZ01HL006007 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · fiscal years 2008 · $384,475 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:59 UTC. The ranking covers the 200 most relevant of 17 PubMed records, and a shared surname and initials can bring in a namesake. All 17 on PubMed
- Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.N Engl J Med · 2022362 citationsRCR 26.3
- Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.N Engl J Med · 2009354 citationsRCR 8.7
- 283 citationsRCR 9.7
- 172 citationsRCR 4.2
- Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.PLoS Med · 2017119 citationsRCR 4.3
- 102 citationsRCR 2.7
- Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres.Br J Haematol · 202166 citationsRCR 4.8
- 59 citationsRCR 1.5
- Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant.Br J Haematol · 201956 citationsRCR 3.2
- Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease.Blood Adv · 202151 citationsRCR 2.8